Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 6/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799965 | 0.85 | NAMPT (0.52) | NAMPT | |
| SCHEMBL7799029 | 0.85 | NPC1 (0.52) | HDAC6NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7790575 | 0.80 | ALDH1A1 (0.43) | HDAC6NAMPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7801296 | 0.80 | HDAC6 (0.41) | HDAC6NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7796730 | 0.78 | HDAC6 (0.46) | HDAC6ALDH1A1MAPK1 | |
| SCHEMBL7789527 | 0.76 | HDAC1 (0.47) | HDAC6NAMPTSMN1; SMN2 | |
| SCHEMBL7790576 | 0.75 | HDAC1 (0.48) | HDAC6NAMPTALDH1A1 | |
| SCHEMBL7801235 | 0.75 | HDAC1 (0.48) | HDAC6NAMPTALDH1A1 | |
| SCHEMBL7795317 | 0.75 | HDAC1 (0.48) | HDAC6NAMPTALDH1A1 | |
| SCHEMBL7796732 | 0.74 | NAMPT (0.40) | HDAC6NAMPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885NAMPT 1262/4885TAS1R3 3620/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885NAMPT 1262/4885TAS1R3 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.